References
The Lancet. COVID-19: fighting panic with information. Lancet. 2020;395(10224):537.
CineHi M, Quattrociocchi W Galeazzi A, Valensise CM, Emanuele Brugnoli E, Schmidt AL, et al. The COVID-19 social media infodemic. arXiv. 2020;arXiv:2003.05004v1.
Zagury-Orly I, Schwartzstein RM. Covid-19: A reminder to reason. N Engl J Med. 2020; Apr 28. doi: 10.1056/NEJMp2009405.
Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8): e124. https://doi.org/10.1371/journal.pmed.0020124
Ioannidis JP. A fiasco in the making? As the coronavirus pandemic takes hold, we are making decisions without reliable data. Stat. 2020;Mar 17;17.
Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R. et al. COVID-19 antibody seroprevalence in Santa Clara county, California. medRxiv 2020.04.14.20062463; doi: https://doi.org/10.1101/2020.04.14.20062463
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178: 104787.
Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 2020 Mar 20;105949. doi: 10.1016/j.ijantimicag.2020.105949.
Molina JM, Delaugerre C, Goff JL, Mela-Lima B, Ponscarme, D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical beneit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;Mar 20:105949. doi: 10.1016/j.ijantimi-cag.2020.105949
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.